pharmacokinetic properties of systemically active, 1629t

prophylaxis regimens and approximate costs, 1626t

Antihistamines, 440t, 711, 822t, 975, 976t

for allergic rhinitis, 432, 433t

for anaphylaxis, 687–688, 689t

for rhinitis, 436–437

and sleep, 1764, 1776

Antimalarials, 707

Antimicrobials, 1328–1330t

costs of therapy, 1335

dosing, 1335–1340

toxicities, 1331–1334

Antimotility drugs, 1461

Antimycotic pulse therapy, 1627

Antineoplastics, and lactation, 1003t

Antioxidants, 1265

as photoprotective agents, 853

Antiplatelet agents, 658

Antipseudomonal β-lactam, 460

Antipseudomonal penicillins, 674

Antipsychotics

for acute agitation, 1846

for acute mania, 1844–1845

fo

r

b

ip

o

la

r

d

e

p

r

e

s

s

io

n

,

1

8

3

7

,

1

8

4

7

fo

r

c

r

it

ic

a

lly

ill

p

a

t

ie

nt

s

,

1

2

0

8

a

n

d

lith

ium

,

1

8

4

3

t

A

n

t

i

p

y

r

e

t

i

c

s

,

1

6

6

5

A

n

t

i

r

e

t

r

o

v

i

r

a

l

t

h

e

r

a

p

y

(

A

R

T

)

,

9

9

6

A

n

t

i

s

p

a

s

m

o

d

i

c

s

,

1

1

8

5

fo

r

I

B

S

,

5

3

5

A

n

t

i

s

p

a

s

t

i

c

i

t

y

a

g

e

n

t

s

,

1

1

8

5

A

n

t

i

t

h

y

m

o

c

yt

e

g

l

o

b

u

l

i

n

(

A

T

G)

,

7

2

2

–

7

2

3

A

n

t

i

t

h

y

r

o

i

d

d

r

u

g

s

,

t

e

r

a

t

o

g

e

n

i

c

e

ffe

c

t

s

,

9

7

3

t

A

n

t

i

v

i

r

a

l

s

a

dv

e

r

s

e

e

ffe

c

t

s

o

f,

1

3

3

4

t

in

fe

b

r

ile

n

e

utr

op

e

nic

p

a

t

ie

nt

,

1

5

6

9

fo

r

H

B

V

,

1

6

7

7

in

immun

o

c

o

mp

r

o

mis

e

d

p

a

t

ie

nt

s

,

1

6

5

4–

1

6

5

5

A

n

z

e

m

e

t

(

s

e

e

D

o

l

a

s

e

t

r

o

n

)

A

p

i

d

r

a

(

s

e

e

I

n

s

u

l

i

n

g

l

u

l

i

s

i

n

e

)

A

p

i

x

a

b

a

n

,

1

3

0

7

t

fo

r

p

r

e

v

e

nt

io

n

o

f

s

tr

o

ke

,

3

1

7

–

3

1

8

fo

r

s

tr

o

ke

p

r

e

v

e

nt

io

n

,

1

7

8

fo

r

w

a

r

fa

r

in

th

e

r

a

p

y

,

2

0

0

A

p

o

k

y

n

(

s

e

e

A

p

o

m

o

rp

h

i

n

e

)

A

p

o

m

o

rp

h

i

n

e

(

A

p

o

k

y

n

)

,

1

2

5

1

t

,

1

2

5

4

t

,

1

2

6

2

A

p

r

a

c

l

o

n

i

d

i

n

e

(

I

o

p

i

d

i

n

e

)

,

1

1

5

2

A

p

r

e

m

i

l

a

s

t

fo

r

p

la

qu

e

p

s

o

r

ia

s

is

,

8

4

1

fo

r

P

s

A

,

8

4

3

A

p

r

e

p

i

t

a

n

t

(

E

m

e

n

d

)

,

1

2

8

,

4

7

2

t

,

9

4

2

t

fo

r

C

I

N

V

,

4

7

1

–

4

7

3

,

4

7

2

t

,

4

7

4

t

,

4

7

5

fo

r

P

O

N

V

,

4

7

8

t

A

p

ri

s

o

(

s

e

e

M

e

s

a

l

a

m

i

n

e

)

A

q

u

a

c

e

l

A

g

(

s

e

e

S

i

l

v

e

r

s

u

l

fa

d

i

azi

n

e

c

r

e

a

m

)

A

q

u

aD

E

K

c

h

e

wa

b

l

e

t

a

b

l

e

t

,

4

5

7

t

p. 2

2

9

1

p. 2

2

9

2

A

q

u

A

D

E

K

l

i

q

u

i

d

,

4

5

7

t

A

q

u

a

r

e

t

i

c

s

,

5

7

9

–

5

8

0

A

r

a

n

e

s

p

(

s

e

e

D

a

rb

e

p

o

e

t

i

n

a

l

fa)

A

R

B

s

(

s

e

e

A

n

g

i

o

t

e

n

s

i

n

r

e

c

e

p

t

o

r

b

l

o

c

k

e

r

s

(

A

R

B

s

)

)

A

r

fo

r

m

o

t

e

r

o

l

,

4

2

0

t

A

r

g

a

t

r

o

b

a

n

,

1

7

8

A

ri

p

i

p

r

az

o

l

e

(

A

b

i

l

i

fy)

,

1

2

6

7

,

1

7

3

9

,

1

7

9

7

t

,

1

7

9

9

t

fo

r

a

c

ut

e

a

g

it

a

t

io

n

,

1

8

4

6

fo

r

a

c

ut

e

ma

nia

,

1

8

4

4–

1

8

4

5

,

1

8

4

5

t

a

n

d

b

ip

o

la

r

d

e

p

r

e

s

s

io

n

,

1

8

4

7

fo

r

b

ip

o

la

r

dis

o

r

d

e

r

,

1

8

4

9

t

fo

r

d

e

v

e

lop

me

nt

a

l

dis

o

r

d

e

r

s

,

1

8

5

7

–

1

8

5

8

fo

r

dy

s

lip

id

e

mia

,

1

8

0

4

fo

r

hyp

e

rp

r

o

la

c

t

in

e

mia

,

1

8

0

3

fo

r

s

c

h

iz

op

hr

e

nia

,

1

7

8

9

,

1

7

9

1

t

,

1

7

9

2

,

1

7

9

3

,

1

7

9

3

t

A

ri

p

i

p

r

az

o

l

e

l

a

u

r

o

x

i

l

,

1

7

9

5

t

A

ri

p

i

p

r

az

o

l

e

m

o

n

o

h

y

d

r

a

t

e

,

1

7

9

5

t

Armodafinil, 1777, 1779

ARNI (see Angiotensin receptor-neprilysin inhibitor (ARNI))

Aromatase inhibitor (Letrozole), 959, 960, 1013, 1972

for endometriosis, 1020

for polycystic ovary syndrome, 1012t

Arsenic trioxide, 469t

for AML, 2027

ART (see Antiretroviral therapy (ART))

Artemisinin, 1695

Artesunate, 1696

Arylcycloalkylamines, 1885

Asacol HD (see Mesalamine)

Ascorbic acid (vitamin C), 657–658, 918, 942t, 961

for anemia, 1931

Asenapine (Saphris), 1797t, 1799t

for acute mania, 1845t

for bipolar disorder, 1849t

for hyperprolactinemia, 1803

for schizophrenia, 1790, 1791t

Asparaginase (Elspar), 469t, 1982t, 1996, 1996t

neurotoxicity of, 1985, 1985t

preparations, 2018

Aspirin, 220, 692, 694, 705, 870–871, 870t, 881, 887, 888t, 1307t, 1312, 1313–1314

for ACS, 238t

for AMI, 251

and clopidogrel, 1315

for diabetes, 167

for end-of-life care, 87

gastric damage, 490, 491

GERD and, 503t

hypertension and, 144

induced anaphylaxis, 694

for PAD, 167–168

for STEMI, 360

for stroke prophylaxis, 2242

toxicity from, 67–70

Astepro (see Azelastine)

Ataluren, 452

Atazanavir (ATV), 120t, 128, 942t, 1579t

Atenolol, 258, 688, 1271t, 1272, 2261t

in hypertension, 159t

for MI, 253

Atezolizumab, 469t

ATG (see Antithymocyte globulin (ATG))

Ativan (see Lorazepam)

Atomoxetine, 1856, 1868t, 1869–1870

Atorvastatin, 46t, 110t, 116, 117t, 120t, 130, 171, 258, 924, 942t

for prostate cancer, 2086

Atovaquone-proguanil (Malarone), 49, 1697t, 1700, 1701

Atovaquone suspension

for mild to moderate PJP, 1603–1604

for toxoplasmosis, 1606

Atracurium, 2198

Atropine, 321

for end-of-life care, 89

Atrovent (see Ipratropium bromide)

Attapulgite, 2161

ATV (see Atazanavir (ATV))

Augmentin, 1325t

for aerobic gram-positive cocci, 1326t

for gram-negative aerobes, 1327t

Auvi-Q, 446t

Avanafil, and ED, 2265

Avastin (see Bevacizumab)

Avelox (see Moxifloxacin)

Avobenzone, 821, 849t, 852

Avycaz, 1325t

Axitinib, 470t

AZA (see Azathioprine (AZA))

Azacitidine, 469t

Azactam (see Aztreonam)

Azathioprine (AZA), 56, 626, 709, 712t, 713t, 718, 720–721, 881, 883, 918t, 928

for inflammatory bowel disease, 521t, 523–524

for ophthalmopathy, 1067

therapy for Wegener granulomatosis, 628

Azelaic acid, for comedonal acne, 827

Azelastine (Optivar), 437, 439t, 440t, 441t, 1165

for allergic rhinitis, 432

Azelastine HCl (Dymista), 441t

Azilsartan medoxomil, for hypertension, 154t

Azithromycin (Zithromax), 460, 690, 927, 1325t, 1326t, 1720, 1727

adverse effects of, 1332t

for Campylobacter infection, 1459

for chronic asthma, 399

for MAC, 1619

for nongonococcal urethritis, 1515

for travelers’ diarrhea, 1461t

for typhoid fever, 1456

Azole antifungals, 1624, 1625, 1639

drug interactions, 1639

risk factor C, 1628

for VVC, 1525

Azopt (see Brinzolamide)

Aztreonam (Azactam), 463, 1326t

for aerobic gram-positive cocci, 1326t

for anaerobes, 1328t

for CAPD-associated peritonitis, 1476t

for CNS infections, 1373t

for cystic fibrosis, 461t

dosing of, 1336t

for gram-negative aerobes, 1327t

for skin and soft tissue infections, 1550

for UTI, 1497t

Azulfidine (see Sulfasalazine)

B

Bacampicillin (Spectrobid), 1326t

Bacillus Calmette-Guérin vaccine, 1616

Bacitracin, 819

Baclofen, 1186t, 1224

B

a

c

t

ri

m

(

s

e

e

T

ri

m

e

t

h

o

p

ri

m

-

s

u

l

fa

m

e

t

h

o

x

az

o

l

e

)

B

a

l

s

a

l

azi

d

e

,

5

2

1

t

,

5

2

3

t

B

a

l

s

a

m

o

f

P

e

r

u

,

8

2

2

t

B

a

rb

i

t

u

r

a

t

e

s

,

9

4

2

t

(

s

e

e

a

l

s

o

S

e

d

a

t

i

v

e

s

)

GE

R

D

a

n

d

,

5

0

3

t

B

a

rl

e

y

m

a

l

t

e

x

t

r

a

c

t

,

2

1

5

9

t

B

a

s

i

l

i

x

i

m

a

b

,

7

2

3

B

az

e

d

o

x

i

fe

n

e

(

B

ZA

)

,

1

0

3

5

B

C

G

(

B

a

c

i

l

l

e

C

a

l

m

e

t

t

e

-

Gu

é

ri

n

)

v

a

c

c

i

n

e

,

1

4

2

7

B

E

A

C

O

P

P

,

fo

r

H

L

,

2

0

4

1

B

e

c

l

o

m

e

t

h

a

s

o

n

e

fo

r

a

lle

r

g

ic

r

h

init

is

,

4

4

2

fo

r

e

n

d

-

o

flife

c

a

r

e

,

8

7

B

e

c

l

o

m

e

t

h

a

s

o

n

e

d

i

p

r

o

p

i

o

n

a

t

e

(

B

e

c

o

n

a

s

e

A

Q

)

,

4

4

1

t

fo

r

B

P

D

,

2

1

7

6

B

e

c

o

n

a

s

e

A

Q

(

s

e

e

B

e

c

l

o

m

e

t

h

a

s

o

n

e

d

i

p

r

o

p

i

o

n

a

t

e

)

B

e

l

a

t

a

c

e

p

t

,

7

2

2

B

e

l

i

m

u

m

a

b

,

7

1

0

–

7

1

1

,

7

1

0

t

,

7

1

2

t

,

7

1

3

t

B

e

l

s

o

m

r

a

(

s

e

e

S

u

v

o

r

e

x

a

n

t

)

B

e

l

v

i

q

(

s

e

e

L

o

r

c

a

s

e

ri

n

)

B

e

n

a

d

ryl

(

s

e

e

D

i

p

h

e

n

h

y

d

r

a

m

i

n

e

)

B

e

n

az

e

p

ri

l

in

hyp

e

r

t

e

n

s

io

n

,

1

5

3

t

fo

r

v

a

s

c

ula

r

d

e

me

nt

ia

,

2

2

4

2

B

e

n

d

a

m

u

s

t

i

n

e

(

T

r

e

a

n

d

a)

fo

r

C

L

L

,

2

0

3

4

drug

int

e

r

a

c

t

io

n

w

ith

s

mo

kin

g

,

1

9

0

6

t

B

e

n

d

a

m

u

s

t

i

n

e

,

4

6

9

t

,

2

0

4

0

t

B

e

n

d

a

m

u

s

t

i

n

e

p

l

u

s

ri

t

u

x

i

m

a

b

(

B

R

)

,

2

0

3

4

B

e

n

z

a

t

h

i

n

e

p

e

n

i

c

i

l

l

i

n

G,

1

5

1

9

–

1

5

2

0

t

B

e

n

z

o

d

i

az

e

p

i

n

e

s

,

9

4

2

t

,

1

2

1

4

,

1

2

2

4

,

1

7

3

8

t

,

1

7

9

0

(

s

e

e

a

l

s

o

S

e

d

a

t

i

v

e

s

)

a

b

u

s

e

a

n

d

d

e

p

e

n

d

e

n

c

e

,

1

7

5

4

,

1

7

7

1

–

1

7

7

3

fo

r

a

c

ut

e

a

g

it

a

t

io

n

,

1

8

4

6

a

dv

e

r

s

e

e

ffe

c

t

s

,

1

7

4

1

fo

r

a

g

it

a

t

e

d

b

e

h

a

v

io

r

s

,

2

2

4

3

fo

r

A

ka

th

is

ia

,

1

7

9

9

a

lc

o

h

o

l

w

ith

dr

a

w

a

l,

1

8

9

4

a

n

d

a

nt

e

r

o

gr

a

d

e

a

mn

e

s

ia

,

1

7

4

1

b

r

e

a

s

t

milk

,

1

7

4

4

v

s. b

u

s

p

ir

o

n

e

,

1

7

4

6

c

linic

a

l

p

r

o

file

s

o

f,

1

7

3

7

t

C

N

S

s

t

imula

nt

s

,

1

8

8

3

a

n

d

c

o

gnit

iv

e

imp

a

ir

me

nt

,

1

7

4

1

fo

r

c

r

it

ic

a

lly

ill

p

a

t

ie

nt

s

,

1

2

0

8

fo

r

d

e

p

r

e

s

s

iv

e

dis

o

r

d

e

r

s

,

1

8

1

5

t

drug

int

e

r

a

c

t

io

n

,

1

7

4

3

w

ith

s

mo

kin

g

,

1

9

0

7

t

dur

a

t

io

n

o

f

tr

e

a

tme

nt

,

1

7

4

2

a

n

d

fa

lls

,

1

7

4

1

p. 2

2

9

2

p. 2

2

9

3

a

n

d

GA

B

A

-

A

r

e

c

e

p

t

o

r

s

,

1

7

3

9

for GAD, 1736

GERD and, 503t

induced sedation, management of, 1744

and lactation, 1776

LSD, 1886

for LTCF, 2229

mechanism of action, 1736–1737

for panic disorder, 1748

physiological factors influencing, 1744

for PMDD, 1025

and pregnancy, 1776

and respiratory depression, 1741

for SAD, 1751

for schizophrenia, 1785

sedative-hypnotics, 1881

and sleep, 1764, 1776, 1861

tolerance of, 1771–1773

use during lactation, 1743–1744

use in pregnancy, 1743–1744

withdrawalsyndrome, management of, 1742–1743

Benzoic acid, 1626

Benzophenones, 849t, 852

Benzoyl peroxide, for maculopapular acne, 828–829

Benzphetamine, 762

Benztropine (Cogentin), 1250t

for Akathisia, 1800t

for Parkinsonism, 1799

Benzyl alcohol, 822t

Bepotastine (Bepreve), 439t, 1165

Bepreve (see Bepotastine)

β-adrenergic agonists, 992

β-adrenergic blockers

for Akathisia, 1799

for patients with CKD, 617

for vascular dementia, 2242

β-adrenergic blocking agents, 313

β-adrenergic receptor blockers, 1061, 1751–1752

β-blockers, 544, 549–550, 942t

for ACS, 238t, 246, 257–258

adrenergic blocking agents, 271

alcohol withdrawal, 1896

benefits of, 257–258

CAD and, 214

carvedilol vs. metoprolol, 288–289

in HFrEF, 287–289

in HTN, 295

for hypertension, 140, 149t, 159t

metoprolol vs. carvedilol, 288–289

for MI, 257–258

in severe heart failure, 289

teratogenic effects, 973t

for thyroid storm, 1067–1068

β-hydroxy-β-methylglutaryl-CoA (HMG-CoA), 247

β-lactam, 455, 460–461, 697–698, 1564

adverse effects of, 1332t

and aminoglycoside, 1563

antibiotics, 460–461

double combinations, 1563

for febrile neutropenia, 1563

Betamethasone, 994

β2

-adrenergic agonists, 503t

β2